Australia's Mesoblast rises on FDA support for heart failure drug approval

Mesoblast

11/03/2024 01:06

** Shares of Mesoblast  MSB.AX  rise as much as 15.9% to
A$0.365, their highest since Nov. 30, 2023
    ** Stock posts its biggest intraday gain since Jan. 19
    ** Drug developer says U.S. FDA supports accelerated 
approval pathway  for rexlemestrocel-L, its heart failure drug
    ** Over 15.2 shares change hands, compared with the 30-day
average volume of 2.9 mln shares
    ** Stock up 1.6% YTD based on last close



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))